CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
1997

Impact of Granulocyte Colony-Stimulating Factor on Chemotherapy for Lung Cancer

Sample size: 63 publication Evidence: high

Author Information

Author(s): M Fukuoka, N Masuda, S Negoro, K Matsui, T Yana, S Kudoh, Y Kusunoki, M Takada, M Kawahara, M Ogawara, N Kodama, K Kubota, K Furuse

Primary Institution: Osaka Prefectural Habikino Hospital; National Kinki Central Hospital

Hypothesis

Does the addition of granulocyte colony-stimulating factor (rhG-CSF) to CODE chemotherapy improve survival in patients with extensive-stage small-cell lung cancer?

Conclusion

The use of rhG-CSF with CODE chemotherapy significantly prolongs survival and increases dose intensity in patients with extensive-stage small-cell lung cancer.

Supporting Evidence

  • Patients receiving rhG-CSF had a median survival of 59 weeks compared to 32 weeks for those who did not.
  • The overall response rate was 97% in the rhG-CSF group versus 84% in the control group.
  • Patients treated with rhG-CSF experienced a significant increase in dose intensity of chemotherapy drugs.

Takeaway

This study found that giving a special medicine called rhG-CSF along with chemotherapy helps people with a type of lung cancer live longer and get more medicine without getting too sick.

Methodology

Patients were randomized to receive CODE chemotherapy alone or with rhG-CSF, and their survival and response rates were compared.

Potential Biases

Potential biases in patient selection and treatment allocation could affect the results.

Limitations

The study may not be generalizable to all patients with small-cell lung cancer due to specific inclusion criteria.

Participant Demographics

Patients aged 18-75 with extensive-stage small-cell lung cancer, including both males and females.

Statistical Information

P-Value

0.004

Confidence Interval

95% CI, 45.6-90.9 for rhG-CSF group; 95% CI, 24.4-41.4 for control group

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication